Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 13;10(4):e0123555.
doi: 10.1371/journal.pone.0123555. eCollection 2015.

Urinary biomarkers at early ADPKD disease stage

Katja Petzold  1 , Diane Poster  2 , Fabienne Krauer  2 , Katharina Spanaus  3 , Gustav Andreisek  4 , Thi Dan Linh Nguyen-Kim  4 , Ivana Pavik  5 , Thien Anh Ho  6 , Andreas L Serra  7 , Laura Rotar  8
Affiliations

Urinary biomarkers at early ADPKD disease stage

Katja Petzold et al. PLoS One. .

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a decline in renal function at late disease stage when the majority of functional renal parenchyma is replaced by cystic tissue. Thus, kidney function, assessed by estimated glomerular filtration rate (eGFR) does not well represent disease burden in early disease. Here, we investigated various urinary markers for tubular injury and their association with disease burden in ADPKD patients at early disease course.

Methods: ADPKD patients between 18 and 40 years with an eGFR greater or equal to 70 ml per min per 1.73m2 were eligible for this cross-sectional study. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), and Uromodulin (UMOD) were investigated by Enzyme-Linked Immunosorbent Assay. Clara Cell Protein 16 (CC16) was investigated by Latex Immuno Assay. Cryoscopy was performed to assess urine osmolality and Urinary Albumin-to-Creatinine Ratio (UACR) was calculated. The association and the predictive properties of the markers on eGFR and height adjusted total kidney volume (htTKV) was evaluated using multiple regression analysis, incorporating different control variables for adjustment. Internal bootstrapping validated the obtained results.

Results: In 139 ADPKD patients (age 31 ±7 years, mean eGFR of 93 ± 19 ml per min per 1.73 m2) the total kidney volume was negatively correlated with eGFR and UMOD and positive associated with age, UACR, KIM-1 and urine osmolality after adjustment for possible confounders. Urine osmolality and htTKV were also associated with eGFR, whereas no association of CC16, NGAL and UMOD with eGFR or htTKV was found.

Conclusion: UACR and urinary KIM-1 are independently associated with kidney size but not with renal function in our study population. Urine osmolality was associated with eGFR and kidney volume following adjustment for multiple confounders. Despite statistical significance, the clinical value of our results is not yet conceivable. Further studies are needed to evaluate the property of the aforementioned biomarkers to assess disease state at early ADPKD stage.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Estimated glomerular filtration rate (eGFR) and parameter distribution.
Fig 2
Fig 2. Total kidney volume (TKV) and parameter distribution.
See this image and copyright information in PMC

References

    1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–1301. 10.1016/S0140-6736(07)60601-1 - DOI - PubMed
    1. Meijer E, Boertien WE, Nauta FL, Bakker S, van Oeveren W, Rook M, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis. 2010;56(5):883–895. 10.1053/j.ajkd.2010.06.023 - DOI - PubMed
    1. Blanco G, Wallace DP. Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2013;305(6):F797–812. 10.1152/ajprenal.00248.2013 - DOI - PMC - PubMed
    1. Briggs JP. The hunt for the perfect biomarker for acute kidney injury: back to gamma-trace? Kidney Int. 2008;74(8):987–989. 10.1038/ki.2008.426 - DOI - PubMed
    1. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182–188. 10.1602/neurorx.1.2.182 - DOI - PMC - PubMed

Publication types